

Tuesday, October 22, 2019

PosterID	Presenter	Abstract Title
T-001	Cheng Chang	Prospectively Applied Quantitative Translational Analysis to Optimize the Clinical Development of PF-06751979: A - site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor
T-002	Kenta Yoshida	A tumor growth inhibition-overall survival model for atezolizumab in first-line non-small cell lung cancer based on IMpower150 study
T-003	Saugat Adhikari	Advancing the design of combination drug regimens through integrated PKPD modeling and simulation to improve GBM chemotherapy
T-004	Thanh Bach	Population Pharmacokinetic Model of Ox fendazole and Metabolites in Healthy Adults Following Single Ascending Doses
T-005	Yangbing Li	Joint modeling of survival time and tumor size data in metastatic breast cancer
T-006	Micha Levi	Population Pharmacokinetic and Exposure Efficacy Analyses of Deutetrabenazine in Patients with Moderate to Severe Tardive Dyskinesia
T-007	Elyes Dahmane	Exposure-response analysis to assess the concentration-QTc relationship of Psilocybin/Psilocin
T-008	Abhishek Sathe	A Pharmacokinetic Simulation Study to Assess Performance of a Sparse Blood Sampling Approach to Quantify Early Drug Exposure
T-009	Elliot Offman	Trial Simulation Framework to Inform a Comparative PK Trial of Pegaspargase in Pediatric Patients with Acute Lymphoblastic Leukemia
T-010	Jaeseong Oh	Population pharmacokinetic modeling of Opiranserin and its active metabolite in young and elderly adult subjects
T-011	Sergio Iadevaia	Evaluation of the performance characteristics of azacitidine +/- pevonedistat (TAK-924) clinical trials using a mathematical model linking blast dynamics to hematologic improvement in patients with acute myeloid leukemia (AML)
T-012	Arnab Mukherjee	Longitudinal Exposure-Response Analysis of Rectal Bleeding (RB) and Stool Frequency (SF) Scores in Patients with Moderate to Severe Ulcerative Colitis (UC) Treated with Tofacitinib
T-013	Qiang Lu	Use of a Semi-mechanistic Population Pharmacokinetic/Pharmacodynamic (Pop PK/PD) Analysis to study Exposure : Response (E:R) Relationships and drug efficacy in Acid Sphingomyelinase Deficiency (ASMD) Adult Patients Treated with Olipudase alpha, a Recombinant Human Acid Sphingomyelinase Enzyme
T-014	Brian Maas	A Review of Applications of Clinical Trial Simulation in the Past Decade
T-015	Beln P.Solans	Application of the Optimal Design Approach to improve Therapeutic Drug Monitoring of Busulfan in Children receiving Hematopoietic stem cell transplantation (HSCT)
T-016	Akshita Chawla	A Model Based Meta-Analysis to study the effect of glucagon-like peptide (GLP-1) receptor agonists on body weight in obese and type 2 diabetic populations
T-017	Lyndsey Meyer	Modeling Fibrosis Progression in NAFLD and NASH

T-018	Jun Li	Impact of endogenous production on pharmacokinetics of one-compartment model having simultaneous first-order and Michaelis-Menten elimination
T-019	Daryl Fediuk	Population Pharmacokinetic (POPPK) Analyses of Ertugliflozin (ERTU) in Select Ethnic Populations
T-020	Kyle Baron	Model-based Dose Selection for a GnRH Receptor Antagonist in Endometriosis and Uterine Fibroids (UF) to Reduce Symptoms While Preventing Lumbar Spine Bone Mineral Density (BMD) Loss
T-021	Ivy Song	Population Pharmacokinetic Modeling and Simulations of rhPTH(1-84), a Recombinant Human Parathyroid Hormone, to Determine Dosing in Pediatric Patients with Chronic Hypoparathyroidism
T-022	Navin Goyal	Appropriate design of paediatric clinical trials - a careful balancing act?
T-023	Natalie Schmitz	Use of Population Pharmacokinetic Modeling and Simulation to Design a Bioequivalence Study of IV Baclofen
T-024	Bojan Lalovic	Sleep Efficacy Exposure Response (ER) Analyses of data from two Phase 3 Trials of Oral Lemborexant, a Dual Orexin Receptor Antagonist, in Subjects with Insomnia Disorder
T-025	Cheng Cui	Influence of the cytochrome P450 gene polymorphism (CYP2D6 and CYP2C19) on the pharmacokinetics of YL-0919 in Chinese healthy subjects: a population pharmacokinetic analysis
T-026	Fulya Akpinar Singh	Development of a mechanistic PK-PD model to guide siRNA therapies
T-027	Daryl Fediuk	Population Pharmacokinetic (POPPK) /Exposure-Response (ER) Analyses of Varenicline in Adolescent Smokers
T-028	Husain Z Attarwala	Development of a Translational Population Pharmacokinetic-Pharmacodynamic Model of mRNA-1944 Encoding Antibody Against Chikungunya Virus in Rats and Non-Human Primates
T-029	Wojciech Krzyzanski	Age-structured Population Model of DNA-label Distribution During Cell Cycle
T-030	Kei Ogawa	Quantitative Analysis on the Relationship between Demographic Characters and Efficacy on the Longitudinal Change of Hot Flashes: A Model-based Meta-analysis (MBMA) in Patients with Vasomotor Symptoms (VMS)
T-031	Karthik Lingineni	Towards Achieving Regulatory Endorsement of a Disease Progression Model-based Clinical Trial Simulation Tool for Duchenne Muscular Dystrophy An Exemplar using Clinical Data from the North Star Ambulatory Assessment
T-032	Yue Gao	Population pharmacokinetic analysis of dupilumab in adult patients with chronic rhinosinusitis with nasal polyposis
T-033	Panli Cardona	A Population Pharmacokinetics and Pharmacodynamics Model of L-Ornithine Phenylacetate in Patients with Hepatic Cirrhosis
T-034	Sunil Sreedharan	Population Pharmacokinetic Modeling and Exposure-Response Analysis of Probuphine implants in Opioid Use Disorder Subjects
T-035	Siyan Xu	Exposure-response analysis for efficacy and safety of IDH305, a novel IDH1 inhibitor, in advanced cancer patients
T-036	Yulia Vugmeyster	Extending dosing interval of bintrafusp alfa (M7824) from every 2 weeks to every 3 weeks dosing

T-037	Shu-Pei Wu	Understanding the Fundamentals of PK/PD Index Analysis - Toward a Better Experimental Design and Analysis
T-038	Irene Bae	Comparison of Physiologically Based versus Empirical Subcutaneous Absorption Pharmacokinetic Models for Monoclonal Antibodies
T-039	Xueting Yao	A Population Pharmacokinetic Model Describing Enterohepatic Circulation of Teriflunomide Sodium in Chinese Healthy Volunteers
T-040	Xiaoyu Yan	External validation of pharmacokinetic models for prolonged dexmedetomidine infusion in adult critically ill patients
T-041	Shuai HU	Evaluations on the renal function improvement effect of drug A in multiple myeloma patients
T-042	Shen Cheng	Elucidating the Disposition of Nano-engineered Mesenchymal Stem Cells using Pharmacokinetic Modeling
T-043	Daren Austin	Weighting for Godot. Is Population Pharmacokinetics in Phase 3 worth the bother?
T-044	Seth Robey	Application of a novel virtual case-matched control (VCMC) approach for benchmarking tumor responses in patients with melanoma treated with pembrolizumab and reduced-dose ipilimumab (KEYNOTE-029) against historical data
T-045	Isabelle Pouliquen	Optimal paediatric dosing of commonly prescribed essential medicines
T-046	Shu Yang	Exposure-efficacy analysis for ribociclib using a variety of exposure metrics
T-047	Steve Choy	A Population Pharmacokinetic Model of KPL-716 in Healthy Volunteers and Patients with Atopic Dermatitis
T-048	Sara Soufsaf	PBE and a novel PKPD metric: How to assess regimen equivalence in ADHD therapy?
T-049	Fangrui Cao	A Population Pharmacokinetics Analysis of HMS5552, a Novel glucokinase activator, in Chinese T2DM Patients
T-050	francois gaudreault	Model-Informed Reverse Translational Strategy to Inform the Clinical Pharmacokinetics and First-in-Human Dose Projection of HP1/2: A Humanized Alpha-4-Integrin Antibody
T-051	jinju.guk@inserm.fr	Modelling the dose-effect relationship between DAV132, an activated charcoal based product, and fecal concentration of moxifloxacin in healthy volunteers
T-052	Marion Dehez	Population pharmacokinetic (PK) analysis of lanreotide autogel in patients with clinical symptoms associated with inoperable malignant intestinal obstruction
T-053	JONATHAN CHAUVIN	Novel user-friendly applications for dose individualization of sunitinib and imatinib
T-054	Marion DEHEZ	Population pharmacokinetic model of lanreotide autogel in Chinese patients with acromegaly
T-055	Fiona Glassman	Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema using Data from the COMPACT Phase III and Open-Label Extension Studies
T-056	Inyoung Hwang	Population pharmacokinetic analysis of LC51-0255, a novel selective sphingosine-1-phosphate 1 receptor modulator, in healthy male volunteers
T-057	Sameed Ahmed	Sex-specific Computational Models for Blood Pressure Regulation in the Rat

T-058	Mason McComb	Generalized Population Modeling, a Pharmacometrics Paradigm for Integrating Machine Learning Algorithms: A Case Study of Insulin Related Metabolomic Biomarkers in Mexican Americans
T-059	Francis Gibbons	Multiscale model identifies optimal schedule for treatment of Acute Myeloid Leukemia in vitro with MCL1 inhibitor AZD5991
T-060	Shuhua Hu	Incorporation of a time-dependent loss mechanism into the delay process
T-061	Sihang Liu	Single Objective Genetic Algorithm Based Approach for Optimal Population Pharmacokinetic/Pharmacodynamic (PK/PD) Model Selection for Clinical Trial Data Associated with Schizophrenia
T-062	Evgeny Metelkin	LikelihoodProfiler Is a Software Package for Practical Identifiability Analysis for the Large-Scale Dynamic Models
T-063	Freya Bachmann	OptiDose: Computing the optimal individual dosing regimen with constraints on model states to include side effects
T-064	Tommy Li	Application of a tumor penetration model for the prediction of tumor target engagement and dose justification
T-065	Kiersten Utsey	Impact of Partition Coefficient Prediction Methods on PBPK Model Output Using a Unified Tissue Composition
T-066	Michael Dolton	A Physiologically Based Pharmacokinetic Model of Vismodegib: Deconvoluting the Impact of Saturable Plasma Protein Binding, pH-dependent Solubility and Nonsink Permeation
T-067	Felix Stader	Aging does not impact the magnitude of drug-drug interactions - a proof of concept study using physiologically-based pharmacokinetic modelling
T-068	Lilly East	Model-informed Drug Development Using PBPK Modeling and Simulations: Glibenclamide following Intravenous Administration
T-069	Zhoumeng Lin	Assessing factors influencing tumor delivery efficiency of nanoparticles in tumor-bearing mice using a physiologically based pharmacokinetic modeling and simulation approach
T-070	Xiaomei Liu	Application of physiologically based pharmacokinetic (PBPK) modeling to predict fetal exposure to dolutegravir
T-071	Pavel Balazki	Physiologically-based Quantitative Systems Pharmacology integrates Drug Development and Precision Medicine in Diabetes
T-072	cibele falkenberg	Application of Quantitative Systems Pharmacology (QSP) model of COPD progression for evaluating a novel mechanism targeting oxidative stress and inflammation in the lung.
T-073	Bradley Niesner	Translational estrogen receptor (ER) modeling to predict a clinically efficacious dosing regimen for an oral selective estrogen receptor down regulator (SERD)
T-074	Jason Chan	Application of a QSP model to dose selection for a BTK inhibitor in rheumatoid arthritis

T-075	Sergey Smirnov	Development of quantitative systems pharmacology (QSP) model of systemic lupus erythematosus and its application to explore possible mechanisms of alterations in serum IFN1 resulting from anti-IFNAR1 treatment
T-076	Marco Albrecht	QSP of dabrafenib metabolism: enzyme induction and mechanistic DDI prediction
T-077	Violeta Balbas-Martinez	Systems Pharmacology model characterizing the main immune components involved in Crohn's Disease to test new therapeutic scenarios.
T-078	Abed Alnaif	Fast calibration of Quantitative Systems Pharmacology models using linearized statistical properties and quadratic programming optimization
T-079	Victor Sokolov	A modeling workflow for quantitative systems pharmacology: Evaluation of MATLAB SimBiology vs. other MATLAB and R-based functionalities
T-080	Dwaipayan Mukherjee	Quantitative Systems Pharmacology Model of Acute Myeloid Leukemia: Prediction of Clinical Response Rates for Standard of Care Chemotherapies
T-081	Hugo Geerts	UNDERSTANDING CLINICAL OUTCOME OF ADUCANUMAB TRIALS IN ALZHEIMER USING A QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL
T-082	Evan Wang	Towards an understanding of hERG potency variability derived from patch clamp protocols
T-083	Lin Lin	Applying Metropolis-Hastings sampling to QSP model to understand the variability in individual animal responses to anti-CTLA4 in CT26 syngeneic mouse model
T-084	Alison Betts	A population QSP model to capture individual tumor growth inhibition responses to anti-CTLA4 therapy in CT26 syngeneic mouse model
T-085	Kristophe Diaz	A quantitative systems pharmacology model simulating the effect of Tau antibodies on the inter-cellular spread of tau in Tauopathies
T-086	Iraj Hosseini	Benchmarking Optimization Methods for Parameter Estimation in Quantitative Systems Pharmacology Models
T-087	Tatiana Karelina	Influence of neuronal protein degradation pathways on tau pathology studied by Quantitative Systems Pharmacology model
T-088	Yanguang Cao	Using a mechanism-based stochastic model to predict tumor evolution and survival outcomes in patients with metastatic colorectal cancer: a retrospective analysis in 599 patients
T-089	Galina Lebedeva	From stem cell to erythrocyte and platelet: QSP model of erythropoiesis and thrombopoiesis for assessing the impact of pharmacological interventions.
T-090	Fulya Akpınar Singh	Virtual Patient Generation Strategies for Non-alcoholic Fatty Liver Disease
T-091	Peter Bloomingdale	Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain
T-092	Douglas Chang	Development of a mechanistic representation of a stable solid tumor

T-093	Christina Friedrich	A qualitative and quantitative framework to assess the value of QSP modeling in pharmaceutical development
T-094	Oleg Demin	Workflow for development of QSP models of Immune Response requires appropriate software infrastructure
T-095	Mathangi Gopalakrishn	A Quantitative Model-Based Framework to Optimize Clinical Outcomes in Neonatal Opioid Withdrawal Syndrome using Real World Data
T-096	France Mentre	New version of PFIM for optimal design in nonlinear mixed effects models using R S4
T-097	France Mentre	Bayesian individual dynamic predictions of biomarkers and risk of event in joint modelling (with uncertainty): a comparison between Stan, Monolix and NONMEM
T-098	Olivier Barriere	vpcstats: a new, flexible, powerful and efficient R package to compute VPC percentiles and prediction intervals
T-099	Evgeny Metelkin	"Heta" is a New Declarative Language to Define the Large-Scale Systems Pharmacology and Systems Biology Models
T-100	Andreas Noack	Fast evaluation of experimental designs in non-linear mixed effects models with the PuMaS package
T-101	Roberta Bursi	QT/TdP Risk Screen: a web-based tool for the early identification and real time assessment of drug-induced proarrhythmic and torsade de pointes safety risk
T-102	Vijay Ivaturi	Comparison of non-compartmental analysis results between PKNCA, PuMaS.NCA and Phoenix WinNonlin
T-103	Vijay Ivaturi	Bioequivalence.jl: A suite of routines for bioequivalence (BE) analysis for the Julia language
T-104	Mark C Peterson	COMPLIMENTARY SHINY AND WIKI APPLICATIONS PROVIDE A DIGITAL WORKBENCH, ENABLING RAPID, RELIABLE, CROSS-STUDY, CROSS-INDICATION CONTEXTUALIZATION FOR ONGOING PROGRAMS